{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:56:04Z","timestamp":1790582164879,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03804-z","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:13:29Z","timestamp":1790579609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"7","key":"3804_CR1","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1111\/dom.70723","volume":"28","author":"T Koufakis","year":"2026","unstructured":"Koufakis T, Kokkinos A, le Roux CW. Why lifestyle alone is insufficient in obesity: biological evidence, conceptual analogies and a legacy of missed opportunities in patient care. Diabetes Obes Metab. 2026;28(7):5424\u201334. https:\/\/doi.org\/10.1111\/dom.70723.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3804_CR2","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1111\/dom.70666","volume":"28","author":"N Eisa","year":"2026","unstructured":"Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):4818\u201327. https:\/\/doi.org\/10.1111\/dom.70666.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3804_CR3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/00015385.2026.2676368","volume":"81","author":"N Devrikis","year":"2026","unstructured":"Devrikis N, Karanikola F, Patoulias D, et al. Beyond sarcopenia and frailty: the underrecognised contribution of adiposity to vulnerability in older adults. Acta Cardiol. 2026;81(4):546\u20137. https:\/\/doi.org\/10.1080\/00015385.2026.2676368.","journal-title":"Acta Cardiol"},{"issue":"3","key":"3804_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321\u201335. https:\/\/doi.org\/10.1159\/000521241.","journal-title":"Obes Facts"},{"issue":"1","key":"3804_CR5","doi-asserted-by":"publisher","first-page":"e2553323","DOI":"10.1001\/jamanetworkopen.2025.53323","volume":"9","author":"Z Wang","year":"2026","unstructured":"Wang Z, Wang L, Zhang X, et al. Body composition changes after bariatric surgery or treatment with GLP-1 receptor agonists. JAMA Netw Open. 2026;9(1):e2553323. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.53323.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 4","key":"3804_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3804_CR7","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"3804_CR8","doi-asserted-by":"publisher","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","volume":"5","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Suppl 1):A16\u20137. https:\/\/doi.org\/10.1210\/jendso\/bvab048.030.","journal-title":"J Endocr Soc"},{"issue":"7","key":"3804_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.14740\/jocmr4987","volume":"15","author":"S Uchiyama","year":"2023","unstructured":"Uchiyama S, Sada Y, Mihara S, et al. Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type\u00a02 diabetes. J Clin Med Res. 2023;15(7):377\u201383. https:\/\/doi.org\/10.14740\/jocmr4987.","journal-title":"J Clin Med Res"},{"issue":"6","key":"3804_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12061172","volume":"12","author":"G Cavaliere","year":"2023","unstructured":"Cavaliere G, Cimmino F, Trinchese G, et al. From obesity-induced low-grade inflammation to lipotoxicity and mitochondrial dysfunction: altered multi-crosstalk between adipose tissue and metabolically active organs. Antioxidants. 2023;12(6):1172. https:\/\/doi.org\/10.3390\/antiox12061172.","journal-title":"Antioxidants"},{"key":"3804_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102253","volume":"101","author":"J Bolte","year":"2025","unstructured":"Bolte J, Smelter AA, Norton L. Are we giving too much weight to lean mass loss? Mol Metab. 2025;101:102253. https:\/\/doi.org\/10.1016\/j.molmet.2025.102253.","journal-title":"Mol Metab"},{"issue":"4","key":"3804_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells15040318","volume":"15","author":"YS Hah","year":"2026","unstructured":"Hah YS, Hwang J, Lee SJ, et al. Decoding the endocrine code of skeletal muscle: myokines, exerkines, and inter-organ crosstalk in metabolic health and disease. Cells. 2026;15(4):318. https:\/\/doi.org\/10.3390\/cells15040318.","journal-title":"Cells"},{"issue":"7","key":"3804_CR13","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/dom.15620","volume":"26","author":"D Rubino","year":"2024","unstructured":"Rubino D, Bjorner JB, Rathor N, et al. Effect of semaglutide 2.4\u00a0mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: patient-reported outcomes from the STEP 1-4 trials. Diabetes Obes Metab. 2024;26(7):2945\u201355. https:\/\/doi.org\/10.1111\/dom.15620.","journal-title":"Diabetes Obes Metab"},{"key":"3804_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70991","author":"N Alfaris","year":"2026","unstructured":"Alfaris N, Kushner RF, Li J, et al. Tirzepatide for obesity in adults \u2265\u200965\u2009years: a post hoc analysis of the SURMOUNT and SUMMIT clinical trials. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70991.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3804_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1210\/jc.2018-00952","volume":"104","author":"DL Alba","year":"2019","unstructured":"Alba DL, Wu L, Cawthon PM, et al. Changes in lean mass, absolute and relative muscle strength, and physical performance after gastric bypass surgery. J Clin Endocrinol Metab. 2019;104(3):711\u201320. https:\/\/doi.org\/10.1210\/jc.2018-00952.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3804_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-019-00545-w","volume":"105","author":"C Beaudart","year":"2019","unstructured":"Beaudart C, Rolland Y, Cruz-Jentoft AJ, et al. Assessment of muscle function and physical performance in daily clinical practice: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Calcif Tissue Int. 2019;105(1):1\u201314. https:\/\/doi.org\/10.1007\/s00223-019-00545-w.","journal-title":"Calcif Tissue Int"},{"key":"3804_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2021.100005","volume":"1","author":"L Alexander","year":"2022","unstructured":"Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: an Obesity Medicine Association (OMA) Clinical Practice Statement 2022. Obes Pillars. 2022;1:100005. https:\/\/doi.org\/10.1016\/j.obpill.2021.100005.","journal-title":"Obes Pillars"},{"issue":"24","key":"3804_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"21","key":"3804_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase\u00a03 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"issue":"10516","key":"3804_CR20","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(25)01375-3.","journal-title":"Lancet"},{"issue":"21","key":"3804_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751","volume":"135","author":"CK Wong","year":"2025","unstructured":"Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025;135(21):e194751. https:\/\/doi.org\/10.1172\/JCI194751.","journal-title":"J Clin Invest"},{"issue":"1","key":"3804_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","volume":"32","author":"DJ Drucker","year":"2026","unstructured":"Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026;32(1):47\u201357. https:\/\/doi.org\/10.1038\/s41591-025-04124-5.","journal-title":"Nat Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03804-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:13:30Z","timestamp":1790579610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03804-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":22,"alternative-id":["3804"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03804-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Theocharis Koufakis has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Sanofi, Roche Diagnostics, ELPEN, Krka, and Novo Nordisk; honoraria for advisory boards from Novo Nordisk and Boehringer Ingelheim; and has participated in sponsored studies by Eli Lilly, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. Theocharis Koufakis is an Editorial Board member of\n                      Advances in Therapy\n                      . Theocharis Koufakis was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Djordje S. Popovic declares relationships with Abbott, Alkaloid, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and W\u00f6rwag Pharma. Dimitrios Patoulias is an Editorial Board member of\n                      Advances in Therapy\n                      . Dimitrios Patoulias was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Anastasios Tentolouris and Paschalis Karakasis declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously published studies and does not contain any new studies with human participants or animals performed by any of the authors. Ethical approval was therefore not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}